Conferences - Results from #300

SUO 2022: Using Biomarkers and Somatic Testing to Guide Treatment Choice December 3, 2022

SUO 2022: Intermediate Risk: New Trials and Horizons December 3, 2022

SUO 2022: Geographic Variation in Utilization of Doublet Therapy for Metastatic Prostate Cancer December 3, 2022

SUO 2022: External Validation of a Digital Pathology-Based AI Model Predicting Metastasis and Death in High and Very High Risk Men on NRG/RTOG 9902 Phase III Trial December 3, 2022

SUO 2022: Looking Towards the Future: Non-Muscle Invasive Bladder Cancer Trials Reading Out in 24 Months December 3, 2022

SUO 2022: Utility of Cxbladder Monitor in Surveillance December 3, 2022

SUO 2022: BCG Naïve - FDA: 1 Year from Symposia December 3, 2022

SUO 2022: “Remote” Monitoring in Urologic Cancer: The Case for Home Based Testing in Bladder Cancer December 3, 2022

SUO 2022: Revisiting Neoadjuvant Therapy Before Prostatectomy December 2, 2022

SUO 2022: Addressing Mental Illness and Suicidality in Men With Prostate Cancer December 2, 2022

SUO 2022: The Joseph A. Smith Jr. Mentorship Award Lecture December 2, 2022

SUO 2022: A Phase 1 Dose-escalation Study of UGN-301 (Zalifrelimab) as Monotherapy and in Combination with Other Agents in Patients with Recurrent Non-muscle Invasive Bladder Cancer December 2, 2022

SUO 2022: A Phase 3 Single-Arm Study of UGN-102 as Primary Chemoablative Therapy in Patients with Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer December 2, 2022

SUO 2022: Real Life Impact of Cxbladder Tests on Diagnosis and Surveillance of Bladder Cancer December 2, 2022

SUO 2022: Use of Exogenous Testosterone in The Setting Of Screening, Active Surveillance, and After Treatment of Localized Disease December 2, 2022

SUO 2022: Comparison of Administration Route for UGN-101 on Upper Tract Urothelial Carcinoma: A Multi Center Evaluation December 2, 2022

SUO 2022: Long-term Outcomes of Treatment with UGN-101, A Mitomycin-containing Reverse Thermal Gel, For Primary Chemoablation of Low-grade Upper Tract Urothelial Carcinoma (LG UTUC) December 2, 2022

SUO 2022: Bipolar Androgen Therapy in Advanced Prostate Cancer December 2, 2022

SUO 2022: Diagnostic Performance and Safety of 18F-rhPSMA-7.3 PET in Patients with Newly Diagnosed Prostate Cancer: Results from a Phase 3, Prospective Multicenter Study (LIGHTHOUSE) December 2, 2022

SUO 2022: Early Experience with UGN-101 for the Treatment of Upper Tract Urothelial Cancer – A Multi-Center Evaluation of Practice Patterns and Outcomes December 2, 2022

Page 16 of 507